Posted by Michael Wonder on 09 Dec 2021
NICE publish final guidance recommending Aspaveli in adults with ultra rare blood disorder
9 December 2021 - The medicine is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a marketing authorisation in the UK.
Sobi UK announced that NICE has issued the final appraisal decision recommending the use of Aspaveli (pegcetacoplan) in adults with paroxysmal nocturnal haemoglobinuria in England and Wales.
